Condition

Triple-Negative Breast Neoplasms

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions5

Lead sponsors shown2

Clinical trials

2 shown

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)NCT02978716 · 2017-02-02

TERMINATED

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsNCT02834247 · 2016-08-12

TERMINATED

Common interventions

CarboplatinDRUG1GemcitabineDRUG1NivolumabDRUG1TAK-659DRUG1TrilaciclibDRUG1

Leading sponsors

Calithera Biosciences, Inc1G1 Therapeutics, Inc.1

Trial status mix

TERMINATED2

Phase mix

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.